Scientists have made a significant breakthrough in Alzheimer’s research, developing a blood test that promises to revolutionize the early diagnosis and monitoring of the disease.
The study, published in Nature, focuses on a blood protein called MTBR-tau243. Researchers have found that levels of this protein correlate closely with different stages of Alzheimer’s disease.
Alzheimer’s, a devastating neurodegenerative disorder, impairs memory and cognitive function by destroying brain cells. It affects an estimated 55 million people worldwide, making it a global health crisis.
While there’s currently no cure for Alzheimer’s, early detection is crucial. Existing treatments can only manage symptoms and slow progression, underscoring the importance of timely intervention. However, diagnosing Alzheimer’s in its early stages has been challenging, as subtle brain changes often elude conventional blood tests and imaging scans.
Researchers at Washington University in St. Louis have identified a specific blood protein that could revolutionize Alzheimer’s diagnostics.
The protein MTBR-tau243 was first highlighted in an Alzheimer’s study published in August 2023.
That research introduced MTBR-tau243 as an indicator of ‘tau tangles’, toxic protein accumulations in the brains of Alzheimer’s patients.
The new study found that MTBR-tau243 levels accurately reflected brain tau tangle buildup with 92% precision. This held for patients with mild cognitive impairment – often an early sign of Alzheimer’s – as well as those in later stages of dementia.
Patients with mild cognitive impairment showed significantly elevated MTBR-tau243 levels compared to healthy individuals. In advanced cases, these levels skyrocketed by over 200 times.
The researchers conclude that measuring MTBR-tau243 levels could be invaluable for early detection and monitoring the progression of Alzheimer’s disease.
